TAK & GCA differ in vessel involvement when it comes to the 👁👁 > TAK- large vessel lesions > GCA- small vessel vasculitis @RheumNow #ACR20 https://t.co/sa4VEvCKOt

@RheumNow #ACR20 abs1923 prosp cohort study of angiographic lesions in Takayasu’ &GCA: although infrequent new angio lesions more likely in TAK. Improvement is possible in both conditions, more likely to occur in TAK. Change in the branch arteries more dynamic than in the aorta https://t.co/2KsZ6o3vtP

Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% Enormous potential, worth exploring! Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs

Can you give TCZ for GCA with minimal steroids? Everyone hates steroids, right? GUSTO trial: IVMP 500mg x3d +TCZ sc q1w 14/18 achieved clinical remission at 24w (but mean 11w) 13/18 relapse-free 1/18 permanent visual loss Is that tradeoff worth it? #ACR20 ABST0515 @RheumNow https://t.co/H9rgSxL6VP

Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow

RITZAREM (RTX vs AZA maintenance post RTX induction relapsing AAV) what happened post-study? After #ACR19, hope RTX confers ongoing benefit Answer: no. Same decline Is 1g q4m dosing not justified? Does that mean RTX needs to be continued, and in whom? #ACR20 ABST2052 @RheumNow https://t.co/tldGqca8xC

VEXAS! Hot topic of the year #ACR2020 ABS#1953 @RheumNow https://t.co/RIQKsoWbHe

• https://twitter.com/SattuiSEMD/status/1325848802192994304

RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

• Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of R…

L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador

SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.co/WBaWN9d8vs

• Comparison of Two Rituximab Regimens for Induction of Remission in Antineutroph…